Screener
Arbutus Biopharma Corporation ABUS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableTradeCurrent.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Trade accounts payable | $1,462 | $1,173 |
| Research and development accruals | 407 | 412 |
| Professional fee accruals | 1,571 | 1,075 |
| Payroll accruals | 789 | 2,159 |
| Restructuring liabilities | 245 | 640 |
| Total accounts payable and accrued liabilities | $4,474 | $5,459 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's accounts payable?
- Arbutus Biopharma Corporation (ABUS) reported accounts payable of $1.46M in Q1 2026.
- How has Arbutus Biopharma Corporation's accounts payable changed year-over-year?
- Arbutus Biopharma Corporation's accounts payable decreased by 34.7% year-over-year, from $2.24M to $1.46M.
- What is the long-term trend for Arbutus Biopharma Corporation's accounts payable?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's accounts payable has grown at a -17.1% compound annual growth rate (CAGR), from $2.99M to $1.17M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Arbutus Biopharma Corporation's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude